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Abstract 
Bardoxolone methyl has been reported to cause detrimental cardiovascular events in the terminated 
BEACON Phase III human clinical trial via modulation of the renal endothelin pathway. However, the 
effects of bardoxolone methyl administration on the endothelin pathway in the heart are unknown. Our 
purpose in this perspective is to highlight the distinctive opposing roles of the renal and heart endothelin 
pathway in cardiac function. Furthermore, we address the need for further investigation in order to 
determine if bardoxolone methyl has a protective role in cardiac function through the suppression of the 
endothelin pathway in the heart. 
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The endothelin pathway: a protective or detrimental target of bardoxolone methyl on 
cardiac function in patients with advanced chronic kidney disease? 
The paradoxical nature of Bardoxolone methyl (BM) has been widely noted in recent 
scientific literature (Van Laecke, Van Biesen et al. 2014). There are many known anti-
inflammatory and anti-oxidative properties of this drug that have shown promise in 
preclinical studies, including treating complications of diabetes such as retinopathy and 
nephropathy (Camer, Yu et al. 2014).  In addition, phases 1 and II of human clinical trials in 
patients with chronic kidney disease found that BM markedly improved kidney function 
(Pergola, Krauth et al. 2011; Pergola, Raskin et al. 2011). These positive results from the 
earlier phases led to the BEACON phase III human clinical trial in patients with type 2 
diabetes and stage 4 chronic kidney disease (de Zeeuw, Akizawa et al. 2013). However, this 
trial was terminated due to safety concerns centred on an increased incidence of 
cardiovascular events in BM treated patients compared to the placebo group (de Zeeuw, 
Akizawa et al. 2013). This has lead to scepticism in the scientific community as to whether 
BM will ever be used in the future treatment of diseases such as chronic kidney disease. 
The mechanisms contributing to the adverse cardiovascular events seen in patients treated 
with BM in the BEACON trial have since been addressed (Chin, Reisman et al. 2014). It was 
concluded that the modulation of the endothelin pathway provided an explanation of the 
mechanisms by which BM caused an increase in cardiovascular events in participants. It was 
also found that BM was able to suppress the endothelin pathway in the kidneys of chronic 
kidney disease (CKD) induced rodents and healthy cynomolgus monkeys by reducing the 
protein expression of the ETA receptor (Chin, Reisman et al. 2014). In healthy cynomolgus 
monkeys, BM did not affect ETB receptor expression (Chin, Reisman et al. 2014). However, 
in rodents induced with CKD, BM restored ETB receptor levels to those observed in the 
control animals(Chin, Reisman et al. 2014). Thus these results are extremely important in 
trying to explain the detrimental cardiovascular events that occurred in a number of patients 
taking BM in this human clinical trial. Despite this, there are limitations in the creation of this 
conclusion, since only the endothelin pathway of kidney tissue and not also cardiac tissue 
was examined. 
It is well established that renal endothelin 1 (ET-1) has several important functions including 
regulating sodium and water homeostasis, renal blood flow and acid base balance via 
activation of ETA and ETB receptors(Kohan 2006) (Table 1). Furthermore, if the endothelin 
system is suppressed, such as from being targeted by BM, this balance is disturbed causing 
fluid retention, which can lead to heart failure(Kohan 2006). However, it is important to note 
that the endothelin pathway in the heart has a different function to the kidneys. ET-1 in the 
cardiac muscle promotes cardiac hypertrophy and subsequent heart failure via activation of 
ETA receptors(Nasser and El-Mas 2014) (Table 1). Furthermore, both ETA receptor and 
combined ETA/ETB receptor antagonism has been shown to lower blood pressure, and reduce 
infarct size in patients with congestive heart failure (Nasser and El-Mas 2014). Thus, 
suppressing the endothelin pathway in the heart would be protective against adverse 
cardiovascular vascular events.  
In our opinion, due to the differing functions of the endothelin pathway in the kidneys and 
heart, we feel that more evidence is required to conclude that BM treatment caused adverse 
cardiovascular events by suppression of the renal endothelin pathway. Future investigation of 
the effects of BM on cardiac tissue is required in order to determine if BM inhibits ETA 
receptors in the heart causing its protection.  
Table 1 Summary of endothelin system functions in the kidney and vascular system 
 ET-1 ETA receptors ETB  receptors 
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